Maternal Worm Infections Boost Offspring Antiviral Immunity Through Gut Microbiome
A Princeton study finds maternal helminth exposure reshapes the microbiome to produce a metabolite that shields offspring from respiratory viruses.
Summary
Researchers at Princeton discovered that mothers infected with helminths — parasitic worms common before industrialization — pass on enhanced antiviral protection to their offspring. The mechanism works through the gut microbiome: helminth infection alters maternal gut bacteria to produce more indole-3-propionic acid (IPA), a tryptophan-derived metabolite. IPA then triggers interferon type-I (IFN-I) responses in lung tissue, protecting offspring against respiratory syncytial virus (RSV) and influenza A. Human data from chronically helminth-infected populations confirmed enriched tryptophan-metabolizing gut bacteria. Importantly, IPA alone was sufficient to boost antiviral signaling in human bronchial cells, suggesting a potential supplement-based strategy to strengthen respiratory immunity without requiring helminth exposure.
Detailed Summary
Modern industrialized societies have largely eliminated helminth (parasitic worm) infections, but this loss may carry hidden immunological costs. A growing body of research suggests that helminths co-evolved with mammals and shaped immune development in ways we are only beginning to understand. This new study from Princeton University adds a striking transgenerational dimension to that story.
Researchers investigated whether maternal helminth infection could influence offspring immunity, and if so, through what mechanism. Using mouse models, they found that offspring of helminth-infected mothers showed broad, lasting protection against respiratory viruses — including RSV and influenza A — even though the offspring themselves were never infected with helminths.
The key mediator turned out to be the gut microbiome. Helminth infection altered the maternal microbiota in ways that increased production of indole-3-propionic acid (IPA), a metabolite derived from tryptophan. IPA was found to stimulate type-I interferon (IFN-I) signaling in lung epithelial cells, a critical first-line antiviral defense. Crucially, IPA supplementation alone was sufficient to recapitulate this protection, pointing to a concrete, actionable intervention.
The human relevance was supported by microbiome analysis of chronically helminth-infected populations, which showed enrichment of bacteria with high tryptophan metabolic capacity. Additionally, IPA treatment enhanced IFN-I antiviral signaling in human bronchial epithelial cells in vitro, strengthening the translational case.
The implications are significant for both immunology and public health. The findings suggest that industrialization-driven loss of helminths may have inadvertently weakened transgenerational antiviral immunity. IPA supplementation could represent a practical, safe strategy to restore this protection. Caveats include the primarily preclinical nature of the work and the need for clinical trials to confirm efficacy and safety of IPA in humans.
Key Findings
- Maternal helminth infection protects offspring from RSV and influenza A via microbiome-driven mechanisms.
- Helminth-altered maternal gut microbiota produces elevated indole-3-propionic acid (IPA), a tryptophan metabolite.
- IPA alone triggers lung epithelial type-I interferon responses sufficient to confer antiviral protection.
- Helminth-infected human populations show gut microbiomes enriched for tryptophan metabolic capacity.
- IPA treatment boosts antiviral IFN-I signaling in human bronchial epithelial cells in vitro.
Methodology
The study used mouse models of maternal helminth infection combined with respiratory virus challenge in offspring to establish causality. Human microbiome data from chronically helminth-infected populations were analyzed for tryptophan metabolic gene enrichment. In vitro experiments with human bronchial epithelial cells tested IPA's direct effect on IFN-I signaling.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. The majority of mechanistic data are from mouse models, and direct human clinical evidence for IPA supplementation improving antiviral outcomes is not yet available. The authors declare a patent interest in IPA supplementation, which represents a potential conflict of interest.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.